Eventide Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Eventide Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-112,000	Closed	-$11.1M	–	167
2020 Q4	$11.1M	Buy	112,000 +61,000	+120%	+$7.46M	0.17%	106
2020 Q3	$7.24M	Hold	51,000	–	–	0.14%	107
2020 Q2	$10.1M	Hold	51,000	–	–	0.22%	95
2020 Q1	$9.99M	Hold	51,000	–	–	0.32%	85
2019 Q4	$10.5M	Sell	51,000 -122,000	-71%	-$22.6M	0.3%	77
2019 Q3	$26.4M	Hold	173,000	–	–	0.87%	42
2019 Q2	$22.3M	Hold	173,000	–	–	0.68%	55
2019 Q1	$20.4M	Buy	173,000 +133,000	+333%	+$13.4M	0.7%	55
2018 Q4	$3.67M	Hold	40,000	–	–	0.16%	93
2018 Q3	$4.5M	Hold	40,000	–	–	0.17%	101
2018 Q2	$3.69M	Hold	40,000	–	–	0.15%	97
2018 Q1	$3.99M	Sell	40,000 -12,000	-23%	-$1.29M	0.19%	92
2017 Q4	$4.88M	Hold	52,000	–	–	0.25%	85
2017 Q3	$5.29M	Hold	52,000	–	–	0.3%	74
2017 Q2	$3.98M	Hold	52,000	–	–	0.25%	78
2017 Q1	$4.48M	Hold	52,000	–	–	0.3%	75
2016 Q4	$3.34M	Hold	52,000	–	–	0.22%	83
2016 Q3	$3.36M	Hold	52,000	–	–	0.21%	82
2016 Q2	$2.88M	Hold	52,000	–	–	0.18%	86
2016 Q1	$2.17M	Buy	+52,000	New	+$2.41M	0.12%	99

Other funds holding LKFT

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Eventide Asset Management's LKFT Position: Q1 2021 in Review

Eventide Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2021, closing a stake of 112,000 shares — an estimated $11.1M sold.

Eventide Asset Management first reported a position in LKFT in Q1 2016 and held it in 20 quarters. The position peaked at $26.4M in Q3 2019. 132 funds tracked by Wall St. Rank hold LKFT as of Q1 2021.

Eventide Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2021 after selling out during the quarter.
Eventide Asset Management sold 112,000 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2021, an estimated $11.1M.
Eventide Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2016 and held it in 20 quarters.
Eventide Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $26.4M in Q3 2019.
132 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2021.

Based on Eventide Asset Management's 13F filing for Q1 2021, filed 14 May 2021.